Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

被引：0
|
作者：
Lewiecki, E. Michael [1 ]
Dinavahi, Rajani V. [2 ]
Lazaretti-Castro, Marise [3 ]
Ebeling, Peter R. [4 ]
Adachi, J. [5 ]
Miyauchi, Akimitsu [6 ]
Gielen, Evelien [7 ]
Milmont, Cassandra E. [2 ]
Libanati, Cesar [8 ]
Grauer, Andreas [2 ]
机构：
[1] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Univ Fed Sao Paulo, Sao Paulo, Brazil
[4] Monash Univ, Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON, Canada
[6] Miyauchi Med Ctr, Osaka, Japan
[7] Univ Hosp Leuven, Leuven, Belgium
[8] UCB Pharma, Brussels, Belgium
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.
    Lewiecki, E. Michael
    Dinavahi, Rajani V.
    Lazaretti-Castro, Marise
    Ebeling, Peter R.
    Adachi, Jonathan D.
    Miyauchi, Akimitsu
    Gielen, Evelien
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S24 - S24
  • [2] Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
    Cosman, F.
    Crittenden, D. B.
    Adachi, J. D.
    Binkley, N.
    Czerwinski, E.
    Ferrari, S.
    Hofbauer, L. C.
    Lau, E.
    Lewiecki, E. M.
    Miyauchi, A.
    Zerbini, C. A. F.
    Milmont, C. E.
    Chen, L.
    Maddox, J.
    Meisner, P. D.
    Libanati, C.
    Grauer, A.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab
    Cosman, Felicia
    Crittenden, Daria B.
    Ferrari, Serge
    Khan, Aliya
    Lane, Nancy E.
    Lippuner, Kurt
    Matsumoto, Toshio
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [4] One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reduction: Analysis for the Japanese Population of Phase 3 FRAME Extension
    Miyauchi, Akimitsu
    Dinavahi, Rajani
    Crittenden, Daria Barry
    Yang, Wenjing
    Maddox, Judy
    Grauer, Andreas
    Hamaya, Etsuro
    Nakamura, Yoichi
    Shimauchi, Junichiro
    Libanati, Cesar
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 261 - 261
  • [5] Effects of Romosozumab in Postmenopausal Women With Osteoporosis After 2 and 12 Months: Bone Histomorphometry Substudy.
    Chavassieux, Pascale
    Chapurlat, Roland
    Portero-Muzy, Nathalie
    Garcia, Pedro
    Brown, Jacques P.
    Horlait, Stephane
    Libanati, Cesar
    Boyce, Rogely
    Wang, Andrea
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S25 - S25
  • [6] Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
    McClung, Michael R.
    Brown, Jacques P.
    Diez-Perez, Adolfo
    Resch, Heinrich
    Caminis, John
    Meisner, Paul
    Bolognese, Michael A.
    Goemaere, Stefan
    Bone, Henry G.
    Zanchetta, Jose R.
    Maddox, Judy
    Bray, Sarah
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (08) : 1397 - 1406
  • [7] FRACTURE RISK REDUCTION WITH ROMO-SOZUMAB: RESULTS OF A PHASE 3 STUDY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Cosman, F.
    Crittenden, D. B.
    Adachi, J. D.
    Binkley, N.
    Czerwinski, E.
    Ferrari, S.
    Hofbauer, L. C.
    Lau, E.
    Lewiecki, E. M.
    Miyauchi, A.
    Zerbini, C. A. F.
    Milmont, C. E.
    Chen, L.
    Maddox, J.
    Meisner, P. D.
    Libanati, C.
    Grauer, A.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S50 - S51
  • [8] Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
    Silverman, S. L.
    Siris, E.
    Kendler, D. L.
    Belazi, D.
    Brown, J. P.
    Gold, D. T.
    Lewiecki, E. M.
    Papaioannou, A.
    Simonelli, C.
    Ferreira, I.
    Balasubramanian, A.
    Dakin, P.
    Ho, P.
    Siddhanti, S.
    Stolshek, B.
    Recknor, C.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (01) : 361 - 372
  • [9] Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
    S. L. Silverman
    E. Siris
    D. L. Kendler
    D. Belazi
    J. P. Brown
    D. T. Gold
    E. M. Lewiecki
    A. Papaioannou
    C. Simonelli
    I. Ferreira
    A. Balasubramanian
    P. Dakin
    P. Ho
    S. Siddhanti
    B. Stolshek
    C. Recknor
    Osteoporosis International, 2015, 26 : 361 - 372
  • [10] One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
    Lewiecki, E. Michael
    Dinavahi, Rajani V.
    Lazaretti-Castro, Marise
    Ebeling, Peter R.
    Adachi, Jonathan D.
    Miyauchi, Akimitsu
    Gielen, Evelien
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (03) : 419 - 428
12345